Endocrinology

Tirzepatide: Efficacy in Weight Management Explored at ATS 2026

Tirzepatide, a dual GIP/GLP-1 receptor agonist, demonstrates significant efficacy in chronic weight management, offering a new therapeutic option.

Lower-Dose Tirzepatide: Can It Sustain Weight Loss Long-Term?

New evidence examines whether reduced tirzepatide doses can maintain weight loss, with implications for long-term obesity management in primary care.

Oral Orforglipron Sustains Weight Loss After Injectable GLP-1 Therapy

The ATTAIN-MAINTAIN trial shows oral orforglipron preserves most injectable-achieved weight loss at 52 weeks, offering a scalable transition option.

GLP-1 Drugs and Oral Medication Absorption: What Prescribers Need to Know

GLP-1 receptor agonists slow gastric emptying, raising theoretical concerns about altered absorption of time-sensitive oral drugs. Evidence remains thin.

What Still Eludes Us in MASH Research?

MASH (metabolic dysfunction-associated steatohepatitis) is a complex disease, and while we've made strides, key mechanistic details remain elusive. This demands a sharper focus on translational studies that can directly inform clinical practice.

Lorlatinib and New-Onset Diabetes Practical Monitoring for Oncologists

Patients on lorlatinib require vigilant monitoring for hyperglycemia and ketoacidosis, regardless of pre-existing diabetes risk factors. Proactive screening and early intervention are crucial to mitigate potential severe complications and ensure patient saf...

Lorlatinib and the Enigma of Autoantibody-Negative Diabetes

Patients on lorlatinib may develop diabetes with unusual characteristics, including the absence of typical autoantibodies. This presents a diagnostic challenge, requiring clinicians to consider drug-induced etiologies even when initial immunological markers...

Unraveling MASH: Implications for Clinical Practice

A new review in Nature Reviews Gastroenterology & Hepatology clarifies the complex interplay of metabolism, inflammation, and fibrosis in metabolic dysfunction-associated steatohepatitis (MASH). This understanding translates to practical guidance for risk s...

SGLT2 Inhibitors: Promise and Peril in Prader-Willi Syndrome?

SGLT2 inhibitors show potential for managing glycemic control in Prader-Willi Syndrome, but clinicians must be vigilant about the risk of renal complications. This necessitates careful patient selection and close monitoring of kidney function throughout tre...

Opportunistic Osteoporosis Screening from CT Scans A Validated Approach?

Using cranial CT scans for opportunistic osteoporosis screening shows promise, but concerns remain. Addressing methodological criticisms is essential for validating this approach in broader clinical practice.